The infusion of capital accelerates a novel, space‑manufactured eye treatment that could fill a major therapeutic gap in vision‑loss diseases and showcases a new manufacturing model for biotech products.
LambdaVision, a biotech company developing an artificial retina, announced the close of a $7 million seed round. The round was co‑led by Seven Seven Six and Aurelia Foundry Fund with participation from Seraphim Space, providing runway into 2027 for preclinical development and space‑enabled manufacturing.
Comments
Want to join the conversation?
Loading comments...